[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lymphedema-arm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lymphedema-arm":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,50,79,110,140,161,183,215,250,271,299,327],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":36,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100053937","screening-for-bcrl-in-targeted-therapy-for-breast-cancer-100053937",false,"NCT05142800","Screening For BCRL In Targeted Therapy For Breast Cancer","Screening for Edema and Breast Cancer-Related Lymphedema in Patients Undergoing Targeted Therapy for Breast Cancer","Inclusion Criteria:\n\n* Subjects who are receiving treatment in the MGH Breast Cancer Center who are enrolled in a DF\u002FHCC-regulated targeted therapy trial for the treatment of early or metastatic breast cancer or patients being treated with a targeted therapy that may alter their risk of developing edema or BCRL will be eligible.\n* Subjects that will be eligible for the study include:\n* Females between 18 and 80 years of age\n* With a history of breast cancer\n* 4 weeks or more post-surgery\n* With or without edema\n* Undergoing treatment with targeted therapy for early or metastatic disease.\n\nExclusion Criteria:\n\n\\- Patients who cannot attain 90 degrees of shoulder abduction (position of measurement with Perometer).","FEMALE","18 Years","80 Years",{"count":20,"type":21},261,"ESTIMATED","OBSERVATIONAL","This a prospective, longitudinal study designed to track edema and Breast Cancer Related Lymphedema (BCRL) onset in breast cancer patients taking targeted therapy treatments for early and metastatic breast cancer.\n\nA Perometer and Sozo devise will be used to measure volume changes",[25,26,27,28,29,30,31,32,33,34,35],"Lymphedema","Lymphedema Arm","Lymphedema of Upper Arm","Lymphedema of Upper Limb","Lymphedema of the Hands","Edema","Edema Arm","Breast Cancer Lymphedema","Breast Cancer Metastatic","Breast Cancer Stage","Breast Cancer",[25,26,27,28,29,30,31,32,33,34,35],"RECRUITING","2026-07-09",{"date":40,"type":41},"2026-07-13","ACTUAL",{"date":43,"type":41},"2018-12-13",{"date":45,"type":21},"2026-09-30",{"name":47,"class":48},"Massachusetts General Hospital","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":56,"minAge":17,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":65,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":49},"100637656","preoperative-indocyanine-green-lymphography-and-high-frequency-ultrasound-as-predictors-of-lymphaticovenous-anastomosis-outcome-in-post-mastectomy-upper-limb-lymphedema-100637656","NCT07614815","Preoperative Indocyanine Green Lymphography and High-Frequency Ultrasound as Predictors of Lymphaticovenous Anastomosis Outcome in Post-Mastectomy Upper Limb Lymphedema","Inclusion Criteria:\n\n* • Female patients aged 18 to 75 years.\n\n  * Unilateral secondary upper limb lymphedema following mastectomy with axillary lymph node dissection.\n  * Minimum interval of six months from completion of oncological treatment (surgery, radiotherapy, systemic therapy) to enrollment.\n  * ISL clinical stage I or II at the time of enrollment; late stage II eligible if patent lymphatic vessels are identified on preoperative HFUS.\n  * Provision of written informed consent (prospective phase).\n\nExclusion Criteria:\n\n* Bilateral upper limb lymphedema.\n\n  * Active locoregional or distant oncological recurrence.\n  * Prior lymphatic surgery on the affected limb.\n  * Severe peripheral vascular disease.\n  * Pregnancy or planned pregnancy during the study follow-up period.\n  * Documented hypersensitivity to indocyanine green or iodine","ALL","75 Years",{"count":59,"type":21},30,"INTERVENTIONAL",[62],"NA","This study aims to evaluate the predictive value of preoperative indocyanine green (ICG) lymphography and high-frequency ultrasound in determining the outcomes of lymphaticovenous anastomosis (LVA) in patients with post-mastectomy upper limb lymphedema. Patients undergoing LVA surgery will undergo preoperative assessment using ICG lymphography and ultrasound mapping of lymphatic vessels and recipient veins. Surgical outcomes will be assessed clinically and functionally through limb circumference measurements, symptom improvement, and postoperative imaging findings. The study seeks to identify imaging predictors associated with successful LVA outcomes and improved postoperative recovery.",[26,32],[66,67,68],"lymph-venous-anastamosis","ICG","HFUS","NOT_YET_RECRUITING","2026-05-22",{"date":72,"type":41},"2026-05-29",{"date":74,"type":21},"2026-05-27",{"date":76,"type":21},"2028-06-01",{"name":78,"class":48},"Assiut University",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":86,"targetDuration":4,"studyType":60,"phases":88,"briefSummary":89,"conditions":90,"keywords":94,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":49},"100625649","prehabilitation-in-breast-cancer-surgery-100625649","NCT07425379","Prehabilitation in Breast Cancer Surgery","Prehabilitation in Breast Cancer Surgery: A Prospective Randomized Controlled Trial Evaluating Shoulder Function, Pain, Quality of Life and Lymphedema Development","Inclusion Criteria:\n\nWomen aged 18-80\n\nStage I-III invasive breast cancer\n\nScheduled for surgery\n\n≥3 weeks before surgery\n\nNo neoadjuvant therapy\n\nExclusion Criteria:\n\nExercise contraindication\n\nActive shoulder pathology\n\nSevere cardiopulmonary disease\n\nPlanned neoadjuvant therapy",{"count":87,"type":21},54,[62],"This prospective, randomized, assessor-blinded, parallel-group clinical trial evaluates the effectiveness of a home-based upper extremity-focused prehabilitation program in women undergoing breast cancer surgery. Participants will be randomized 1:1 to either prehabilitation or usual care. Primary outcomes include shoulder range of motion and upper extremity function (DASH score). Secondary outcomes include grip strength, pain, fatigue, disability, anxiety\u002Fdepression, and lymphedema incidence up to 2 years postoperatively.",[91,92,26,93],"Breast Cancer (Early Breast Cancer)","Postoperative Shoulder Dysfunction","Cancer Rehabilitation",[95,96,97,98,93,99],"Prehabilitation","Breast Cancer Surgery","Shoulder Range of Motion","Upper Extremity Function","Exercise Therapy","2026-02-23",{"date":102,"type":41},"2026-02-24",{"date":104,"type":21},"2026-03-01",{"date":106,"type":21},"2028-12-01",{"name":108,"class":109},"Bakirkoy Dr. Sadi Konuk Research and Training Hospital","OTHER_GOV",{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":56,"minAge":17,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":60,"phases":119,"briefSummary":120,"conditions":121,"keywords":125,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":139},"100522417","the-n-lva-study-rct-comparing-lva-vs-sham-surgery-in-cancer-related-lymphedema-100522417","NCT06082349","The N-LVA Study: RCT Comparing LVA vs. Sham Surgery in Cancer-related Lymphedema","Effectiveness and Cost-effectiveness of Lymphaticovenous Anastomosis for Cancer Patients Who Suffer From Chronic Peripheral Lymphedema: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Treated for cancer and underwent treatment of either axillary or inguinal lymph nodes or radiotherapy;\n* Early stage lymphedema (ISL I-II) in the upper or lower extremity, and diagnosed by lymphoscintigraphy for the lower extremity;\n* Unilateral lymphedema;\n* Viable lymphatic vessels as determined by indocyanine green (ICG)Lymphography (stage II-III);\n* Refractory lymphedema that underwent at least three months of conservative treatment;\n* Informed consent.\n\nExclusion Criteria:\n\n* History of lymphatic reconstruction in the past 10 years;\n* Late-stage lymphedema of the extremity (ISL classification ≥ II lymphedema) with evident fat deposition and\u002For fibrosis;\n* Patients with active distant metastases, treated with palliative intent;\n* Patients with the active treatment of primary cancer, i.e. surgery, radiotherapy, and\u002For chemotherapy. Note: patients receiving adjuvant targeted and\u002For endocrine treatment are eligible;\n* Edema due to venous insufficiency, evaluated by venous duplex ultrasound of the deep and superficial venous system;\n* Active infection in the lymphedematous extremity;\n* Bilateral lymphedema;\n* Lymphedema present in genital or breast area only;\n* Primary lymphedema;\n* Non-viable lymphatic system as determined by ICG Lymphography (stages IV and V).",{"count":118,"type":21},110,[62],"The goal of this randomized controlled trial is to compare the effectiveness and cost-effectiveness of lymphaticovenous anastomosis (LVA) with sham surgery for patients suffering from unilateral cancer-related lymphedema in either the upper or lower extremity. It aims to answer whether LVA is more effective than sham surgery in terms of improvement in Lymph-ICF score.\n\nA total of 110 participants will be allocated randomly into two groups at a 1:1 ratio. The first group will receive lymphaticovenous anastomosis (LVA), while the second group will undergo sham surgery.",[122,28,123,26,124],"Lymphedema, Secondary","Lymphedema, Lower Limb","Lymphedema of Leg",[126,127,128,129],"Lymphaticovenous anastomosis","Sham surgery","Microsurgery","LVA","2026-01-15",{"date":132,"type":41},"2026-01-16",{"date":134,"type":41},"2023-12-18",{"date":136,"type":21},"2029-03-01",{"name":138,"class":48},"Maastricht University Medical Center",3,{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":4,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":57,"enrollmentInfo":147,"targetDuration":4,"studyType":60,"phases":149,"briefSummary":150,"conditions":151,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":49},"100502661","evaluation-of-combination-therapy-for-upper-extremity-lymphedema-100502661","NCT05825157","Evaluation of Combination Therapy for Upper Extremity Lymphedema","Prospective Evaluation of Combination Therapy for Upper Extremity Lymphedema","Inclusion Criteria:\n\n* Ages 18 to 75 years (inclusive)\n* Life expectancy \\> 2 years\n* Upper limb lymphedema\n* The participant must be eligible for surgical intervention\n* Swelling of 1 limb that is not completely reversed by elevation or compression\n* Stage I-II lymphedema at screening, based on the International Society of Lymphology (ISL) staging system\n* Participants with a history of cancer must have no evidence of disease (NED), have completed breast cancer therapy 3 years prior to enrollment; use of endocrine therapy is allowed.\n* Completion of a full course of complete decongestive therapy (CDT), according to ISL guidelines at least 12 weeks prior to screening, including use of compression garments for at least 12 weeks without change in regimen\n* Willingness to comply with recommended regimen of self care, with consistent use of compression garments from screening through the entire study duration (through the safety follow up visit), excluding the first 3 weeks postoperatively where patients are required to not wear compression. Self bandaging, use of nighttime compression garments, and intermittent pneumatic compression devices are allowed, but the procedures and regimens are expected to remain consistent from screening though the entire study duration.\n* Consistent use of an appropriately sized compression garment for daytime use.\n* Limb volume (LV) in the affected limb and unaffected limb must be at least 10% of each other.\n* Evidence of abnormal bioimpedance ratio, if feasible, based upon unilateral disease: L Dex \\> 10 units.\n* Willingness and ability to comply with all study procedures, including measurement of limb volume, skin biopsy, and preoperative and postoperative imaging studies.\n* Willingness and ability to understand, and to sign a written informed consent form document\n\nExclusion Criteria:\n\n* Edema arising from increased capillary filtration will be excluded (venous incompetence).\n* Inability to safely undergo general anesthesia and\u002For perioperative care related to vascularized lymph node transfer\n* Concurrent participation in a clinical trial of any other investigational drug or therapy, regardless of indication, within 1 month before screening or 5 times the drug's half life, whichever is longer\n* Recent initiation (≤ 12 weeks) of CDPT for lymphedema\n* Other medical condition that could lead to acute limb edema, such as (but not limited to) acute venous thrombosis or heart failure\n* Other medical condition that could result in symptoms overlapping those of lymphedema in the affected limb (e.g., pain, swelling, decreased range of motion)\n* History of clotting disorder (hypercoagulable state)\n* Chronic (persistent) infection in the affected limb\n* Infection of the lymphedema limb within 1 month prior to screening\n* Currently receiving chemotherapy or radiation therapy\n* Body Mass Index (BMI) \\>35\n* Known sensitivity to porcine products\n* Anaphylaxis to iodine\n* Pregnancy or nursing\n* Substance abuse (such as alcohol or drug abuse) within 6 months prior to screening\n* Any reason (in addition to those listed above) that, in the opinion of the investigator, precludes full participation in the study.",{"count":148,"type":21},60,[62],"Investigate whether the addition of the Biobridge scaffold to the standard surgery for vascularized lymph node transfer will improve the outcome of surgical treatment in lymphedema of the upper extremity. Will Biobridge improve upon the low success rate of the currently practiced surgery by facilitating the lymphatic connections to the transplanted node that are crucial to its viability and function.",[26],"2025-12-22",{"date":154,"type":41},"2025-12-24",{"date":156,"type":41},"2023-11-17",{"date":158,"type":21},"2029-01-01",{"name":160,"class":48},"Stanford University",{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":56,"minAge":17,"maxAge":4,"enrollmentInfo":168,"targetDuration":4,"studyType":60,"phases":170,"briefSummary":171,"conditions":172,"keywords":173,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":49},"100610921","lymphovenous-bypass-procedure-for-secondary-prevention-of-lymphedema-in-breast-cancer-100610921","NCT07233863","Lymphovenous Bypass Procedure for Secondary Prevention of Lymphedema in Breast Cancer","Effectiveness of Lymphovenous Bypass Procedure for Secondary Prevention of Lymphedema in Breast Cancer","Inclusion Criteria:\n\n* Breast cancer patients aged ≥ 18 years with an ECOG score \\> 1\n* Breast cancer patients with post-axillary lymph node dissection diagnosed with stage 0 and I lymphedema.\n* Those who have never undergone lymphedema physiotherapy.\n\nExclusion Criteria:\n\n* Patients with dermal backflow before axillary lymph node dissection (ALND).\n* Patients with breast cancer lymphedema who are unable to undergo a 24-month follow-up at Dharmais Cancer Hospital.\n* Patients with iodine allergy, severe asthma, decreased kidney function, pregnancy, or breastfeeding.",{"count":169,"type":21},136,[62],"This study aims to evaluate the effectiveness of the Lymphovenous Bypass (LVB) procedure compared to physiotherapy alone as secondary prevention of lymphedema in breast cancer patients undergoing axillary lymph node dissection.",[26],[35,25],"2025-11-14",{"date":176,"type":41},"2025-11-18",{"date":178,"type":41},"2024-03-18",{"date":180,"type":21},"2028-03-21",{"name":182,"class":109},"Dharmais National Cancer Center Hospital",{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":57,"enrollmentInfo":190,"targetDuration":4,"studyType":60,"phases":192,"briefSummary":194,"conditions":195,"keywords":198,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":214},"100527161","phase-3-a-study-of-a-comprehensive-prevention-program-to-reduce-lymphedema-after-axillary-lymph-node-dissection-in-people-with-breast-cancer-100527161","NCT06144164","A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer","A Prospective Cohort Study of Patients Undergoing ALND for Treatment of Breast Cancer: The Efficacy of a Comprehensive Prevention Program in Decreasing the Incidence of Lymphedema and Improving Quality of Life","Inclusion Criteria:\n\n* Female sex\n* Diagnosis of breast cancer\n* Ages 18 to 75 years\n* Consented for unilateral ALND or for unilateral SLNB with possible ALND\n\nExclusion Criteria:\n\n* Male sex\n* Does not speak English\n* Does not fit into study garment\n* Axillary recurrence\n* History of ALND\n* Requirement of bilateral ALND for the treatment of breast cancer\n* Treatment with SLNB only\n* Known anaphylactic allergy to ICG dye used in ILR\n* Impaired decision-making capacity",{"count":191,"type":21},285,[193],"PHASE3","The purpose of this study to test whether a comprehensive program may help the lymph fluid to drain out of the arm and prevent lymphedema in participants with breast cancer.",[25,26,27,35,196,197],"Breast Carcinoma","Female Breast Cancer",[199,200,25,26,27,201,202,203,204,205],"immediate lymphatic reconstruction","axillary lymph node dissection","Breast cancer","breast carcinoma","female breast cancer","Memorial Sloan Kettering Cancer Center","23-303","2025-11-06",{"date":208,"type":41},"2025-11-10",{"date":210,"type":41},"2023-11-16",{"date":212,"type":21},"2030-03-16",{"name":204,"class":48},7,{"id":216,"slug":217,"hasResults":11,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":221,"eligibilityCriteria":222,"healthyVolunteers":11,"sex":16,"minAge":223,"maxAge":224,"enrollmentInfo":225,"targetDuration":4,"studyType":60,"phases":226,"briefSummary":227,"conditions":228,"keywords":233,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":4},"100606060","effectiveness-of-a-therapeutic-exercise-program-with-specific-upper-limb-exercises-to-reduce-lymphedema-and-neuropathy-in-breast-cancer-patients-a-pre-post-study-lynma-100606060","NCT07170631","Effectiveness of a Therapeutic Exercise Program With Specific Upper Limb Exercises to Reduce Lymphedema and Neuropathy in Breast Cancer Patients: A Pre-post Study (LYNMA)","Effectiveness of a General Therapeutic Exercise Program Including Specific Upper Limb Exercises to Reduce Lymphedema and Peripheral Neuropathy Secondary to Oncological Treatment in Patients With Breast Cancer: A Pre-post Intervention Study (LYNMA)","LYNMA","Inclusion Criteria:\n\n* Patients receiving treatment for breast carcinoma.reatments include surgical procedures (breast-conserving surgery or mastectomy), axillary lymph node dissection, sentinel lymph node biopsy, radiotherapy, chemotherapy, and hormone therapy.\n* Participants must provide authorization from their primary care physician and\u002For oncologist to perform therapeutic exercise.\n* Diagnosis of lymphedema associated with stage I or II breast cancer (Stage 1 or mild: circumference difference less than 4 cm \\[volume difference 10-25%\\] compared to the healthy arm; Stage 2 or moderate: circumference difference between 4 and 6 cm \\[volume difference 25-50%\\] compared to the healthy arm).\n* A score of 4 or higher on the DN4 questionnaire (neuropathic pain)\n\nExclusion Criteria:\n\n* Lack of medical authorization.\n* Pre-existing cardiac pathology prior to cancer diagnosis.\n* Exacerbation of comorbidities.\n* Travel time exceeding 45 minutes to the location where the therapeutic exercise program is conducted.","35 Years","70 Years",{"count":59,"type":21},[62],"This study aims to evaluate the effectiveness of a therapeutic exercise program designed specifically for women with breast cancer. The program includes general exercises along with specific movements for the upper limb to help reduce common side effects of cancer treatment such as lymphedema (swelling of the arm) and neuropathy (nerve pain or numbness). Participants will undergo the exercise program and be assessed before and after to determine improvements in their symptoms and overall quality of life. The goal is to provide evidence that targeted physical therapy can improve recovery and well-being in breast cancer survivors.",[26,229,230,231,232],"Lymphedema Due to Radiation","Lymphedema, Breast Cancer","Peripheral Neuropathy Due to Chemotherapy","Peripheral Neuropathy in Breast Cancer Patient",[234,201,25,235,236,237,238,239,240],"Therapeutic exercise","Peripheral neuropathy","Upper limb exercises","Oncology physiotherapy","Neural mobilization","Neurodynamic techniques","Peripheral nerve ultrasound","2025-09-12",{"date":243,"type":41},"2025-09-18",{"date":245,"type":21},"2026-01",{"date":247,"type":21},"2026-10",{"name":249,"class":48},"Universitat Internacional de Catalunya",{"id":251,"slug":252,"hasResults":11,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":4,"eligibilityCriteria":256,"healthyVolunteers":11,"sex":16,"minAge":223,"maxAge":257,"enrollmentInfo":258,"targetDuration":4,"studyType":60,"phases":259,"briefSummary":260,"conditions":261,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":4},"100558597","immersive-virtual-reality-based-exersice-in-post-mastectomy-lymphedema-patients-100558597","NCT06553183","Immersive Virtual Reality Based Exersice in Post-mastectomy Lymphedema Patients","Immersive Virtual Reality Based Exersice and Shoulder Proprioception and Range of Motion in Post-mastectomy Lymphedema Patients","Inclusion Criteria:\n\n* All the patients will be females.\n* Patients with lymph node dissection.\n* start at least 2 weeks after operation.\n\nExclusion Criteria:\n\n* Vision problems.\n* Medically instable patients.\n* Balance disorders.\n* Other musculoskeletal condition of shoulders.","65 Years",{"count":148,"type":21},[62],"To determine the effect of immersive virtual reality on shoulder proprioception and ROM of post-mastectomy lymphedema patients.",[26],"2024-08-12",{"date":264,"type":41},"2024-08-14",{"date":266,"type":21},"2024-08-15",{"date":268,"type":21},"2025-02-15",{"name":270,"class":48},"Cairo University",{"id":272,"slug":273,"hasResults":11,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":4,"eligibilityCriteria":277,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":278,"targetDuration":4,"studyType":60,"phases":279,"briefSummary":280,"conditions":281,"keywords":285,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":49},"100557041","the-robot-lva-study-robot-assisted-microsurgical-lymphaticovenous-anastomosis-in-breast-cancer-related-lymphedema-100557041","NCT06532955","The Robot-LVA Study: Robot-assisted Microsurgical Lymphaticovenous Anastomosis in Breast Cancer-related Lymphedema","Pilot Study on Robotic Assisted Microsurgical Lymphatico-venular Anastomosis","Inclusion Criteria:\n\n* Female gender;\n* Treated for primary early stage breast cancer;\n* Early stage lymphedema of the arm (stage 1 or 2 on ISL classification);\n* ELV \\> 10%;\n* Suffering from unilateral disease.\n\nExclusion Criteria:\n\n* Male gender;\n* Stage 3 lymphedema of the arm;\n* Receiving current breast cancer treatment;\n* Distant breast cancer metastases;\n* Current substance abuse;\n* History of marcaine or indocyanine green allergy;\n* Non-viable lymphatic system as determined by near infrared imaging;\n* Previous LVA (\\\u003C10 years) in the arm with lymphedema.",{"count":148,"type":21},[62],"This study assesses the performance of robot-assisted microsurgery. Lymphaticovenous anastomosis (LVA) is the most difficult procedure in microsurgery at this moment. The LVA technique is applied to treat for example breast cancer-related lymphedema (BCRL). Therefore, this LVA procedure is compared using a manual expert and the same expert applying robot-assisted LVA.",[25,26,27,28,282,122,283,230,284],"Lymphedema; Surgical","Lymphedema of Limb","Lymphedema, Non-Filarial",[286,128,287,288,289,126,290,129],"Robot-assisted microsurgery","Robot","Robotic-assisted","Robot-assisted","Lymphatico-venular anastomosis","2024-07-30",{"date":293,"type":41},"2024-08-01",{"date":295,"type":41},"2017-06-01",{"date":297,"type":21},"2026-01-01",{"name":138,"class":48},{"id":300,"slug":301,"hasResults":11,"nctId":302,"briefTitle":303,"officialTitle":304,"acronym":305,"eligibilityCriteria":306,"healthyVolunteers":11,"sex":56,"minAge":17,"maxAge":4,"enrollmentInfo":307,"targetDuration":4,"studyType":60,"phases":309,"briefSummary":310,"conditions":311,"keywords":313,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":139},"100444188","added-value-of-reconstructive-lymphatic-surgery-to-usual-care-in-lymphoedema-100444188","NCT05064176","Added Value of Reconstructive Lymphatic Surgery to Usual Care in Lymphoedema","Comparison of Reconstructive Lymphatic Surgery Versus no Surgery, Additional to Decongestive Lymphatic Therapy (Usual Care), for the Treatment of Iymphoedema, Through a Multicentre Randomised Controlled Trial","SurLym","Inclusion Criteria:\n\n* Unilateral or bilateral, primary or secondary lymphoedema of the upper or lower limb\n* If cancer-related lymphoedema, approval for participation in study from oncological specialist (patient participation has to be discussed during Multidisciplinary Oncological Consult); approval if:\n\n  * estimated cancer-related survival is ≥3 years\n  * oncological safety is guaranteed: for instance, time interval since radiotherapy\u002F chemotherapy is ≥3 months\n* Lymphoedema stage 1 to 2b\n* Objective diagnosis of lymphoedema: ≥ 5% volume difference OR ≥ 2 minor\u002F 1 major criteria on lymphoscintigraphy OR presence of IndoCyanineGreen (ICG) dermal backflow\n* Score on Lymph-ICF questionnaire at screening: ≥ 25 \u002F 100 (= moderate level of problems in functioning related to the development of lymphoedema)\n* History of at least 6 months of decongestive lymphatic therapy (DLT) until minimal pitting\n* Age ≥ 18 years\n\nExclusion Criteria:\n\n* Participants with history of liposuction, lymphovenous anastomosis, lymph node transfer\n* Pregnant participants\n* Severe obese participants: BMI\\>35\n* Estimated cancer-related survival is \\\u003C3 years and oncological safety is not guaranteed (e.g. interval since radiotherapy\u002F chemotherapy is \\\u003C3 months)\n* In case of lower limb lymphoedema: presence of chronic venous insufficiency C4, C5, C6; deep venous thrombosis; post-thrombotic syndrome\n* Allergy for ICG, iodine, penicillin and sulphonamides; increased activity of thyroid gland; benign tumour in thyroid; heparin use and severe renal insufficiency",{"count":308,"type":21},180,[62],"The primary objective of this research proposal is to investigate\n\n* in patients with lymphoedema of the upper limb or lower limb (P)\n* the added value of reconstructive lymphatic surgery (I)\n* to the decongestive lymphatic therapy (usual care) (C)\n* on the lymphoedema-specific quality of life (QoL) (O)\n* at 18 months post-surgery\u002F no surgery (T)\n\nConsequently, a multicentre pragmatic randomised controlled trial is performed to give an answer on following research question: 'Is, in addition to usual care - i.e. decongestive lymphatic therapy -, reconstructive lymphatic surgery (intervention group) superior to no surgery (control group), for the treatment of upper or lower limb lymphoedema?'",[312,26,25],"Lymphoedema of Leg",[314,315,316,317],"Reconstructive lymphatic surgery","Decongestive lymphatic therapy","Lymphovenous anastomosis","Lymph node transfer","2024-07-01",{"date":320,"type":41},"2024-07-03",{"date":322,"type":41},"2022-02-01",{"date":324,"type":21},"2026-12",{"name":326,"class":48},"Universitaire Ziekenhuizen KU Leuven",{"id":328,"slug":329,"hasResults":11,"nctId":330,"briefTitle":331,"officialTitle":331,"acronym":332,"eligibilityCriteria":333,"healthyVolunteers":11,"sex":56,"minAge":17,"maxAge":4,"enrollmentInfo":334,"targetDuration":4,"studyType":60,"phases":336,"briefSummary":337,"conditions":338,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":49},"100430737","a-non-randomized-open-label-study-to-evaluate-the-safety-and-effectiveness-of-the-dayspring-technology-for-patients-with-breast-cancer-related-lymphedema-bcrl-after-lymphatic-surgery-100430737","NCT04888975","A Non-randomized, Open-Label Study to Evaluate the Safety and Effectiveness of the Dayspring Technology for Patients With Breast Cancer Related Lymphedema (BCRL) After Lymphatic Surgery","TIGRIS","Inclusion Criteria:\n\n* Males and females ≥ 18 years of age\n* Willing to sign the informed consent and deemed capable of following the study protocol\n* Subjects must have a diagnosis of upper extremity edema and have or will undergo lymphatic surgery with Dr. Nguyen\n* Subjects must have a difference in volume greater than 3% between the limbs.\n\nExclusion Criteria:\n\n* Individuals with a history or presence of a systemic disorder or condition that could place the patient at increased risk from sequential compression therapy\n* Inability or unwillingness to participate in all aspects of study protocol and\u002For inability to provide informed consent\n* Patients with exam results that would prevent safe and effective use of the study device (cellulitis, open-wounds, healing-wounds, etc.)\n* Diagnosis of active or recurrent cancer, or less than 3 months at the time of initial evaluation from the completion of chemotherapy, radiation therapy or primary surgery for the treatment of cancer\n* Patients must not have any diagnosed cognitive or physical impairment that would interfere with use of the device\n* Diagnosis of lipedema\n* Diagnosis of acute infection. The source of the infection must be treated for 2 weeks prior to admittance into the study\n* Diagnosis of acute thrombophlebitis (in last 2 months)\n* Diagnosis of pulmonary embolism or deep vein thrombosis within the previous 6 months\n* Diagnosis of pulmonary edema\n* Diagnosis of congestive heart failure (uncontrolled)\n* Diagnosis of chronic kidney disease\n* Diagnosis of epilepsy\n* Patients with poorly controlled asthma\n* Women who are pregnant, planning a pregnancy or nursing at study entry\n* Participation in any clinical trial of an investigational substance or device during the past 30 days\n* Bilateral limb edema",{"count":335,"type":21},20,[62],"To evaluate the Dayspring Active Wearable Compression Technology in enhancing lymph movement and its safety and effectiveness after lymphatic surgery",[25,230,26],"2021-05-18",{"date":341,"type":41},"2021-05-20",{"date":343,"type":21},"2021-06-01",{"date":345,"type":21},"2021-12-31",{"name":347,"class":348},"Koya Medical, Inc.","INDUSTRY"]